Hyogo, Japan

Takahiro Ochi

This inventor holds 1 USPTO granted patent. Top assignee: Shionogi Company Limited. Active years: 2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takahiro Ochi. Retrieved from https://idiyas.com/inventor/takahiro-ochi-1i9ko19s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Takahiro Ochi and His Work in Bone Research.

Introduction

Takahiro Ochi is an inventor associated with Hyogo, Japan, and Shionogi Company Limited. His patent work concerns methods for isolating osteoclast precursor cells and inducing their differentiation into osteoclasts. The available information identifies 1 patent associated with him.

Latest Patents

Ochi’s patent, “Methods for Isolation of Osteoclast Precursor Cells and Inducing Their Differentiation into Osteoclasts,” describes culturing precursor cells without accessory cells to promote their development into osteoclasts. It also covers isolating precursor cells by culturing peripheral blood or joint fluid without cytokines for one to three weeks.

The patent further describes using the resulting precursor cells or osteoclasts to screen potential treatments for metabolic bone diseases. It also addresses agents identified through that screening process.

Career Highlights

Ochi’s documented invention focuses on laboratory methods relevant to studying osteoclast development and metabolic bone diseases. His work is associated with Shionogi Company Limited.

Collaborations

The provided information names Tomoko Maeda and Ryuji Suzuki as Ochi’s coworkers. No further details about their roles or specific contributions are available.

Conclusion

Takahiro Ochi’s patent describes methods for isolating osteoclast precursor cells, inducing their differentiation, and applying these cells in the screening of potential treatments for metabolic bone diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…